1325216-75-8

Upstream product

• 327-92-4 1,5-difluoro-2,4-dinitrobenzene 
• 1325215-82-4 methyl 2-(5-fluoro-2,4-dinitrophenylamino)acetate 
• 2252-63-3 1-(4-Fluorophenyl)piperazine 

Downstream Products

• 1325216-54-3 6-(4-(4-fluorophenyl)piperazin-1-yl)-7-(4-phenylthiazol-2-ylamino)quinoxalin-2(1H)-one 
• 1325217-11-5 1-(7-(4-(4-fluorophenyl)piperazin-1-yl)-3-oxo-3,4-dihydroquinoxalin-6-yl)thiourea 
• 1325216-99-6 C₂₆H₂₃FN₆O₂S 
• 1325216-86-1 C₁₈H₁₈FN₅O 

Relevant academic research and scientific papers

Quinoxalin-2(1 h)-one derivatives as inhibitors against hepatitis C virus

Hepatitis C virus (HCV) infection is a serious problem worldwide, but no effective drugs are currently available. Through screening of our privileged structure library, quinoxalin-2(1H)-one derivative N-(7-(cyclohexyl(methyl) amino)-3-oxo-3,4-dihydroquinoxalin-6-ylcarbamothioyl)benzamide (compound 1) was identified as potent HCV inhibitor in vitro. Subsequently, a structure-activity relationship analysis was carried out that showed N-(7-(cyclohexyl(methyl)amino) -3-oxo-3,4-dihydroquinoxalin-6-ylcarbamothioyl)furan-2-carboxamide (compound 11, EC50 = 1.8 μM, SI = 9.6), 6-(cyclohexyl(methyl)amino)-7-(4- phenylthiazol-2-ylamino)quinoxalin-2(1H)-one (compound 33, EC50 = 1.67 μM, SI = 37.4), 2-(cyclohexyl(methyl)amino)-3-(4-phenylthiazol-2- ylamino)-7,8,9,10-tetrahydro-5H-pyrido[1,2-a]quinoxalin-6(6aH)-one (compound 60, EC50 = 1.19 μM, SI = 9.27), 8-(cyclohexyl(methyl)amino)-7-(4- phenylthiazol-2-ylamino)pyrrolo[1,2-a]quinoxalin-4(5H)-one (compound 65, EC 50 = 1.82 μM, SI = 9.9), and 6-(diethylamino)-7-(4-phenylthiazol- 2-ylamino)quinoxalin-2(1H)-one (compound 78, EC50 = 1.27 μM, SI = 17.9) acted against HCV. The data from the structure-activity relationship study suggests that quinoxalin-2(1H)-one derivatives exhibited potent activity against HCV.